Virbac acquires Thyronorm for the treatment of feline hyperthyroidism

Virbac, a major player in animal health, has acquired Thyronorm, an innovative product from Norbrook designed to stabilize hyperthyroidism in cats, an endocrine disease affecting more than 10% of older felines. The acquisition, valued at approximately £100 million, is expected to boost the group's revenue and EBITDA margin growth in the first year.

Virbac will distribute Thyronorm, also known as Felanorm, in the United States, the United Kingdom, Australia, and New Zealand. The European market will be gradually integrated into its operations, currently managed by Boehringer Ingelheim and Elanco in Germany. This liquid medication facilitates administration and precise dosing, thus improving the quality of life for affected cats.

With the increasing number of cats in homes, the acquisition of Thyronorm represents a significant strategic step for Virbac. Paul Martingell, CEO of the Virbac Group, emphasizes the company's commitment to innovative solutions for the treatment of chronic animal diseases.